DOCSLIB.ORG

Life Improved Nuvelo

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Life Improved Nuvelo Nuvelo_02ar 5/15/03 3:32 PM Page 1 Life Improved Nuvelo ANNUAL REPORT 2002 Nuvelo_02ar 5/15/03 3:32 PM Page 2 Ted W. Love, MD PRESIDENT, CEO AND DIRECTOR Nuvelo_02ar 5/15/03 3:32 PM Page 3 Nuvelo, Inc. 675 Almanor Avenue Sunnyvale, CA 94085 Dear fellow stockholders, Marching forward–these words articulate the year 2002 for Nuvelo. We have marched forward on a number of important fronts and in my letter to you this year I would like to share with you my enthusiasm for Nuvelo, my appreciation for your support and my optimism for our future. Focus When I joined Nuvelo two years ago, I began to realize that we needed to shift our focus from tools to therapeutics. The value of a therapeutics company, with a significant product on the market, is well established throughout the industry. Given the expertise and assets of the company, a product focus presented the clearest path toward creating a valuable business. Our singular focus is now dedicated to discovering and developing important, life improving therapeutics. It is with this focus in mind that we made some important decisions that have given the company a renewed sense of purpose and direction. In the beginning of 2002, realizing the benefit of accelerating our approach to the market, Nuvelo partnered with Amgen Inc., and brought in the company’s near-term product candidate, alfimeprase. In May of 2002, the company then decided to further strengthen its pharmaceutical focus and financial position by accelerating the completion of its agricultural gene discovery collaboration with BASF Plant Science LLC. Finally, at the end of 2002, the company announced a definitive agreement to merge with Variagenics, Inc. Our perseverance and focus were evidenced as we needed to make some difficult decisions following the completion of our merger with Variagenics in January 2003. Variagenics, located in Cambridge, Massachusetts, has some very important and intriguing technology surrounding molecular diagnostics and pharmacogenomics. While these present interesting business and scientific opportunities, we concluded that they do not fit with our core business objective of developing and commercializing therapeutics. As it is vital to our success that we invest our cash and efforts solely in our therapeutics business, we have decided to seek opportunities to divest the Variagenics business. We want to thank the leadership of Variagenics for their support in achieving this objective and for their hard work and dedication toward creating a valuable business. Nuvelo_02ar 5/15/03 3:32 PM Page 4 Perseverance There are several qualities about Nuvelo that set us apart. First, we have an unyielding perseverance. In our business, success does not come easily, you really have to work at it. We are beginning to see the positive effect of our perseverance as alfimeprase, our lead product candidate, enters Phase II clinical studies for two important indications, peripheral arterial occlusion (PAO) and catheter occlusion. These two medical conditions represent a significant market opportunity and a large patient population that we believe will benefit from this important therapeutic advance. We are privileged to work with Amgen on the development and commer- cialization of this significant product opportunity. Future outlook In conclusion, I would like to look to the future. It is a great privilege to lead Nuvelo. I have a tremendous colleague and mentor in George Rathmann, whom I learn from every day. I have great enthusiasm for our talented team of employees who are inspired by the opportunity to discover and develop important, life improving therapeutics. I have great confidence in our proprietary gene collection. There are many promising product candidates within this collection and we are making important progress toward understanding the biology that will lead us into clinical development. Additionally, we have adopted an opportunistic in-licensing and partner- ing strategy to accelerate the expansion of our product portfolio and our alfimeprase program is poised to deliver “proof of concept” data by the end of 2003. I would like to express my sincere thanks to you, our stockholders and employees for your support. I know that this past year has been particularly difficult. I believe our path is clear and we are indeed marching forward. I thank you for persevering with us. We are committed to building a company that makes a difference to patients, their families and health care providers. There is no greater motivation for the work that we do than to know that our ultimate goal is to improve life. We at Nuvelo thank you for the opportunity and are committed to marching forward. Ted W. Love, MD President, CEO and Director April 2003 George B. Rathmann, PhD CHAIRMAN OF THE BOARD Nuvelo_02ar 5/15/03 3:32 PM Page 5 George B. Rathmann, PhD CHAIRMAN OF THE BOARD Nuvelo_02ar 5/15/03 3:32 PM Page 6 Building Nuvelo 2001 2002 2003 01.01 Ted W. Love, MD joins as 01.02 Collaboration with Amgen Inc. 01.03 Shareholders approve merger president to develop the novel acting with Variagenics, Inc. thrombolytic, alfimeprase 03.01 Ted W. Love, MD appointed 02.03 Combined company changes chief executive officer 02.02 Collaboration with Genetastix name to Nuvelo and begins Corporation to generate fully trading on the Nasdaq with its 04.01 Linda Fitzpatrick appointed human monoclonal antibodies new name and symbol, NUVO senior vice president of human against a proprietary antigen resources utilizing the HuMYTech 02.03 Philippe O. Chambon, MD, PhD, technology general partner of the Sprout 05.01 Peter Garcia appointed Group; Jean-Francois Formela, MD, senior vice president and 04.02 Raised $15 Million in a private general partner at Atlas Ventures chief financial officer placement and Martin Vogelbaum, partner of Apple Tree Partners, join board of 07.01 Collaboration and license agree- 05.02 Accelerated completion of directors as a result of the close ment with Aurora Biosciences agricultural gene discovery of the merger Corporation (now Vertex collaboration with BASF Plant Pharmaceuticals Inc.) to screen Science LLC, strengthening 02.03 IND filed for alfimeprase in secreted proteins and provide the company’s pharmaceutical second indication, catheter selected novel targets for the focus and financial position occlusion development of small molecule drug candidates 06.02 Mary K. Pendergast JD, LLM 03.03 Successful completion of from the U.S. Food and Drug enrollment for our Phase I clinical 08.01 Collaboration with Kirin Brewery Administration and currently at trial with alfimeprase in chronic Co., Ltd., Pharmaceutical Division Elan Corporation, appointed to peripheral arterial occlusion to identify and develop secreted the board of directors proteins and associated antibodies with clinical utility 06.02 Nina Giles joins as vice president of business development 08.01 Raised $21 million in a private placement 06.02 Initiated Phase I clinical trial for alfimeprase in chronic peripheral 10.01 Collaboration with Deltagen, Inc. arterial occlusion to identify and develop therapeutic candidates through research and 09.02 License agreement with UCSF development of novel secreted and Celera Diagnostics involving proteins a large-scale DNA sample collection used to identify genetic 10.01 Patent litigation predispositions that contribute to with Affymetrix, Inc. settled cardiovascular diseases 10.01 Callida Genomics established 11.02 Entered into a definitive merger as a subsidiary to focus on DNA agreement with Variagenics, Inc. chip and sequencing technology 3. NUVELO 2002 ANNUAL REPORT Nuvelo_02ar 5/15/03 3:32 PM Page 7 Marching Forward Focus 1. Advancing Alfimeprase 2. Driving Drug Discovery 3. Maximizing Our Full Potential 4. Harvesting Our Gene Collection 5. Ingredients For Success 4. NUVELO 2002 ANNUAL REPORT Nuvelo_02ar 5/15/03 3:33 PM Page 8 Alfimeprase, unlike other thrombolytic agents, directly dissolves blood clots. In addition, a common protein circulating in the body rapidly inactivates alfimeprase outside of the targeted clot. These unique attributes allow catheter-directed administration of alfimeprase to hold the potential to achieve rapid clot lysis without the risk of bleeding complications. Nuvelo_02ar 5/15/03 3:33 PM Page 9 1 Advancing Alfimeprase • OVERVIEW • HOW IT WORKS • POTENTIAL THERAPEUTIC APPLICATIONS Recognizing the opportunity to march forward and accelerate the company’s transition into a therapeutics company, Nuvelo formed a partnership with Amgen Inc. in early 2002 for the devel- opment and commercialization of alfimeprase. Identified through research programs at Amgen, alfimeprase is a novel acting thrombolytic used to degrade blood clots. Under the terms of the collaboration, Nuvelo is leading clinical development activities and Amgen is responsible for man- ufacturing activities. Amgen will have the option to lead commercialization efforts in which both companies may participate. Both Amgen and Nuvelo share worldwide commercial rights. In the months following the announcement of the collaboration, Nuvelo aggressively got to work on alfimeprase. We began a Phase I clinical trial with alfimeprase in June 2002, marking a major milestone for Nuvelo as the company’s first human trial. The Phase I study, designed to evaluate the safety and pharmacokinetics of alfimeprase in patients with chronic peripheral arterial occlusion (PAO), was conducted in twenty patients in seven centers across the United States. In March of 2003, we successfully completed enrollment in this Phase I trial showing that alfimeprase was safe and well-tolerated with no drug related adverse events. On the heels of this announcement, we also disclosed plans to initiate a multi-national Phase II study in acute PAO patients in the second quarter of 2003. The trial will test the safety and effi- cacy of multiple doses of alfimeprase. Renowned leaders in the field of thrombolysis, Dr. Kenneth Ouriel, chairman of the department of vascular surgery at the Cleveland Clinic, and Jacob Cynamon, professor of clinical radiology and director of the division of vascular and interventional radiology at the Montefiore Medical Center, will serve as the principal investigators for the study.
Load more

Recommended publications
  • Fibrolase: Trials and Tribulations
    Toxins 2010, 2, 793-808; doi:10.3390/toxins2040793 OPEN ACCESS toxins ISSN 2072-6651 www.mdpi.com/journal/toxins Review Fibrolase: Trials and Tribulations Francis S. Markland 1,2,* and Steve Swenson 1,2 1 Department of Biochemistry and Molecular Biology, Cancer Research Laboratory, Keck School of Medicine, University of Southern California, 1303 N. Mission Rd., Los Angeles, CA 90033, USA 2 USC/Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-(323) 224-7981; Fax: +1-(323) 224-7679. Received: 11 March 2010; in revised form: 31 March 2010 / Accepted: 19 April 2010 / Published: 20 April 2010 Abstract: Fibrolase is the fibrinolytic enzyme isolated from Agkistrodon contortrix contortrix (southern copperhead snake) venom. The enzyme was purified by a three-step HPLC procedure and was shown to be homogeneous by standard criteria including reverse phase HPLC, molecular sieve chromatography and SDS-PAGE. The purified enzyme is a zinc metalloproteinase containing one mole of zinc. It is composed of 203 amino acids with a blocked amino-terminus due to cyclization of the terminal Gln residue. Fibrolase shares a significant degree of homology with enzymes of the reprolysin sub-family of metalloproteinases including an active site homology of close to 100%; it is rapidly inhibited by chelating agents such as EDTA, and by alpha2-macroglobulin (). The enzyme is a direct-acting thrombolytic agent and does not rely on plasminogen for clot dissolution. Fibrolase rapidly cleaves the A()-chain of fibrinogen and the B()-chain at a slower rate; it has no activity on the -chain.
    [Show full text]
  • Guidelines on CVD During Pregnancy (TF17) - Task Force Members and Additional Contributors
    Guidelines on CVD during Pregnancy (TF17) - Task Force Members and Additional Contributors Expert Relationship Type of relationship with industry Financial declaration with Industry Blomstrom-Lundqvist Yes A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. Carina - Medtronic : Pacemaker B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Atricure : AF ablation Borghi Claudio Yes A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Menarini International : ACE-inhibitors - Boheringer Ingelheim : Antihypertensive drugs - Recordati International : Antihypertensive drugs - Novartis : Antihypertensive, Heart Failure D - Research funding (departmental or institutional). - Barilla Food Company : Lactotripeptides Cifkova Renata Yes A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : cardiovascular - Daiichi Sankyo : cardiovascular - MSD-SP, Boehringer Ingelheim, Bayer : cardiovascular B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Daiichi Sankyo : cardiovascular - Novartis : cardiovascular D - Research funding (departmental or institutional). - Krka Czech Republic : cardiovascular - Servier Czech Republic : cardiovascular Ferreira J Rafael No
    [Show full text]
  • In Re Nuvelo, Inc. Securities Litigation 07-CV-04056-Declaration of Mark
    BERGER & MONTAGUE, P.C. Sherrie R. Savett Carole A. Broderick Phyllis M. Parker 1622 Locust Street Philadelphia, PA 19103 Tel: (215) 875-3000 Fax: (215) 875-4604 Email: [email protected] cbroderick@bm ,net [email protected] IZARD NOBEL LLP ROBBINS GELLER RUDMAN Jeffrey S. Nobel & DOWD LLP Mark P. Kindall, Bar No 138703 Darren J. Robbins Nancy A. Kulesa Dennis J. Herman 29 South Main Street Eli R. Greenstein Suite 215 S. Ashar Ahmed West Hartford, Ct 06107 Post-Montgomery Center Tel: (860) 493-6292 One Montgomery Street, Suite 1800 Fax: (860) 493-6290 San Francisco, CA 94104 Email: [email protected] Tel: (415) 288-4545 [email protected] Fax: (415) 288-4534 [email protected] Email: [email protected] dennisb@rgrdlaw,corn [email protected] aahmed@rgrdlaw com Co-Lead Counsel for Plaintiffs Liaison Counsel UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA SAN FRANCISCO DIVISION In re NUVELO, INC. SECURITIES Master File No 07-CV-04056-VRW LITIGATION CLASS ACTION DECLARATION OF MARK P. KINDALL IN SUPPORT OF PLAINTIFFS' MOTION FOR CLASS CERTIFICATION DATE: March .3, 2011 I TIME: 10:00 a.rn. I COURTROOM: 6 DECLARATION OF MARK P KINDALL IN SUPPORT OF PLArNTIFFS' MOTION FOR CLASS CERTIFICATION - 07-CV-04056-VRW DECLARATION OF MARK P. KINDALL IN SUPPORT OF PLAINTIFFS' MOTION FOR CLASS CERTIFICATION 2 3 I, Mark P. Kindall, hereby declare as follows: 4 1. I am a partner at the law firm of Izard Nobel LLP, which was appointed Co-Lead 5 Counsel for Plaintiffs in this litigation on September 19, 2007. I have personal knowledge of the 6 facts set forth herein.
    [Show full text]
  • The Development of Stroke Therapeutics: Promising Mechanisms and Translational Challenges
    Neuropharmacology 56 (2009) 329–341 Contents lists available at ScienceDirect Neuropharmacology journal homepage: www.elsevier.com/locate/neuropharm Review The development of stroke therapeutics: Promising mechanisms and translational challenges Margaret M. Zaleska a, Mary Lynn T. Mercado a, Juan Chavez b, Giora Z. Feuerstein b, Menelas N. Pangalos a, Andrew Wood a,* a Discovery Neuroscience, Wyeth Research, CN8000, Princeton, NJ 08543, USA b Translational Medicine, Wyeth Research, Collegeville, PA, USA article info abstract Article history: Ischemic stroke is the second most common cause of death worldwide and a major cause of disability. Received 8 August 2008 Intravenous thrombolysis with rt-PA remains the only available acute therapy in patients who present Received in revised form within 3 h of stroke onset other than the recently approved mechanical MERCI device, substantiating the 29 September 2008 high unmet need in available stroke therapeutics. The development of successful therapeutic strategies Accepted 6 October 2008 remains challenging, as evidenced by the continued failures of new therapies in clinical trials. However, significant lessons have been learned and this knowledge is currently being incorporated into improved Keywords: pre-clinical and clinical design. Furthermore, advancements in imaging technologies and continued Ischemia Neuroprotection progress in understanding biological pathways have established a prolonged presence of salvageable Regeneration penumbral brain tissue and have begun to elucidate the natural repair response initiated by ischemic Inflammation insult. We review important past and current approaches to drug development with an emphasis on Neuroimaging implementing principles of translational research to achieve a rigorous conversion of knowledge from Translational medicine bench to bedside. We highlight current strategies to protect and repair brain tissue with the promise to Drug development provide longer therapeutic windows, preservation of multiple tissue compartments and improved clinical success.
    [Show full text]
  • The Bottom 99
    The Top 100 June 1, 2004 A list of stocks topping our custom 'torpedo’ screen. Updated monthly. ABFI AMER BUSINESS FINL SVCS INC Financials ABGX ABGENIX INC Health Care ADLR ADOLOR CORP Health Care AGEN ANTIGENICS INC/DEL Health Care AGI ALLIANCE GAMING CORP Consumer Cyclicals AKLM ACCLAIM ENMNT INC Technology ALKS ALKERMES INC Health Care ALXN ALEXION PHARMACEUTICALS INC Health Care AMLN AMYLIN PHARMACEUTICALS INC Health Care APHT APHTON CORP Health Care ARNA ARENA PHARMACEUTICALS INC Health Care BIOV BIOVERIS CORP Health Care BMRN BIOMARIN PHARMACEUTICAL INC Health Care BVSN BROADVISION INC Technology CBRX COLUMBIA LABORATORIES INC Health Care CCRD CONCORD COMMUNICATIONS INC Technology CDE COEUR D'ALENE MINES CORP Basic Materials CFFN CAPITOL FEDERAL FINANCIAL Financials COMS 3COM CORP Technology CPN CALPINE CORP Utilities CRAY CRAY INC Technology CRGN CURAGEN CORP Health Care CRXA CORIXA CORP Health Care CYBX CYBERONICS INC Health Care DAL DELTA AIR LINES INC Capital Goods DEPO DEPOMED INC Health Care DMX I-TRAX INC Health Care DRXR DREXLER TECHNOLOGY CORP Technology DSCO DISCOVERY LABORATORIES INC Health Care DV DEVRY INC Capital Goods ELGX ENDOLOGIX INC Health Care EPIX EPIX MEDICAL INC Health Care EXEL EXELIXIS INC Health Care EXLT EXULT INC Capital Goods FCP FALCON PRODUCTS INC Capital Goods FMKT FREEMARKETS INC Technology FXEN FX ENERGY INC Energy GBTVK GRANITE BROADCASTING Consumer Cyclicals GENE OSCIENT PHARMACEUTICALS CORP Health Care GGNS GENUS INC Technology GLFD GUILFORD PHARMACEUTICAL INC Health Care GMRK GULFMARK OFFSHORE
    [Show full text]
  • Healthcare Conference
    25th Annual HEALTHCARE CONFERENCE Healthcare Westin St. Francis San Francisco January 8–11, 2007 JPMorgan cordially invites you to attend the 25th Annual Healthcare Conference, January 8 –11, 2007, at the Westin St. Francis in San Francisco. JPMorgan’s premier conference on the healthcare industry will feature more than 260 public and private companies over four days of simultaneous sessions. In addition, the conference will host topical panel discussions featuring leading industry experts. Preliminary List of Invited Presenting Companies Actelion Ltd Baxter International Inc. Cooper Companies Aetna Incorporated BD (Becton, Dickinson) Coventry Affymetrix, Inc. Beckman Coulter, Inc. Dade Behring Holdings, Inc. Alcon, Inc. Bioenvision, Inc. DaVita Inc. Align Technology, Inc. Biogen Idec deCODE genetics, Inc. Allscripts Healthcare Solutions Inc. Biomet, Inc. Digene Altana Boston Scientific Corporation Digirad Corporation — US American Medical Systems Holdings Inc. Bristol-Myers Squibb Company Diversa Corporation Amerigroup Corp. Cambrex Corporation DJO Incorporated AmerisourceBergen Cardinal Health, Inc. Dyax Corp. Amgen, Inc. Caremark Rx, Inc. Eclipsys Corporation AMN Healthcare Services, Inc. Celgene Corporation Edwards Lifesciences Corporation AmSurg Corporation Cell Genesys Elan Corporation, plc Anadys Pharmaceuticals CENTENE Corporation Eli Lilly and Company Applied Biosystems Group Cephalon, Inc. Emdeon Ariad Pharmaceuticals, Inc. Cerner Corporation Emergency Medical Services Corporation AstraZeneca Group plc Charles River Laboratories,
    [Show full text]
  • Schedule 14A Information
    QuickLinks -- Click here to rapidly navigate through this document SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material Pursuant to §240.14a-12 GILEAD SCIENCES, INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): ý No fee required. o Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0- 11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: o Fee paid previously with preliminary materials. o Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: GILEAD SCIENCES, INC.
    [Show full text]
  • How Scientist/Founders Lead Successful
    HOW SCIENTIST/FOUNDERS LEAD SUCCESSFUL BIOPHARMACEUTICAL ORGANIZATIONS: A STUDY OF THREE COMPANIES Lynn Johnson Langer A DISSERTATION Submitted to the Ph.D. in Leadership & Change Program of Antioch University in partial fulfillment of the requirements for the degree of Doctor of Philosophy May, 2008 This is to certify that the dissertation entitled: HOW SCIENTIST/FOUNDERS LEAD SUCCESSFUL BIOPHARMACEUTICAL ORGANIZATIONS: A STUDY OF THREE COMPANIES prepared by Lynn Johnson Langer is approved in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Leadership & Change. Approved by: ______________________________________________________________________ Alan E. Guskin, Ph.D., Chair date ______________________________________________________________________ Jon Wergin, Ph.D., Committee Member date ______________________________________________________________________ Mitch Kusy, Ph.D., Committee Member date ______________________________________________________________________ Alice Sapienza, DBA, External Reader date Copyright 2008 Lynn Johnson Langer All rights reserved Acknowledgements I arrive at this place in my journey to becoming a scholar supported in love and friendship by so many people. I must thank first and foremost my husband, Eric Langer, who has supported me in many ways, but particularly with my education. I thank my daughter, Julia Annemarie, my study partner. We shout across the hall to each other, complaining and laughing about all the work. I thank her for her support and the opportunity to be a role model. She never once complained about the plays and events I missed because I was away at a residency. I thank my son, Adam and his wife, Megan who through their lives, remind me to follow my dreams. I thank my son, Benjamin, who shows me that through hard work, we can accomplish great things.
    [Show full text]
  • UR-Coeus Sponsor List
    UR-Coeus Sponsor Table (alphabetical by sponsor name) Sponsor Sponsor Code Sponsor Type 2138 21st Century Medicine CORP Sponsor Type Key 1 3M CORP CORP = Corporate 3803 4S3 Bioscience Inc CORP FED = Federal 5207 A. F. Associates Family Medicine ONFA FND = Foundation 2602 A. P. Pharma CORP IND = Individuals 2 A.L. Mailman Foundation FND NYS = New York State 2023 AA Implant Dentistry Research Foundation ONFA OLG = Other Local Gov't 3 AAA Fnd for Traffic Safety ONFA ONFA = Other Non-Fed Agency 2329 aaiPharma Inc CORP VHA = Voluntary Health Agency 3257 Aamjiwnaang First Nations Community ONFA 5345 Aarhus University Hospital ONFA 3713 Aaron Copland Fund for Music, Inc. ONFA 4 AARP Andrus Fdn FND 3853 AB Sciences CORP 3378 AB Vector, Inc CORP 899 Abbott Diagnostics CORP 3864 Abbott Fund FND 14 Abbott Laboratories CORP 5126 AbbVie, Inc. CORP 5854 Abeona Therapeutics CORP 5063 Abington Medical Specialists ONFA 5331 Abington Memorial Hospital ONFA 2835 ABIOMED, Inc. CORP 3687 Ablation Frontiers CORP 5118 Ablynx NV CORP 2053 ABMRF/Fnd for Alcohol Research ONFA 2171 Abortion Rights Mobilization ONFA 3361 Abraxix BioScience, LLC CORP 4953 Abt Associates, Inc. CORP 5037 Academic Gastrointestinal Cancer Consortium ONFA 15 Academic Med Ctr Cons ONFA 3733 Academic Pediatric Association ONFA 3160 Academy of Orofacial Pain ONFA 2122 Academy of Prosthodontics Foundation ONFA 3663 Acadia Pharmaceuticals, Inc. CORP 3273 Accelerate Brain Cancer Cure ONFA 5584 Acceleron Pharma Inc. CORP 5601 Accelovance, Inc. CORP 5940 Accreditation Council Grad Med Educ ONFA 5832 Accriva Diagnostics CORP 3888 AccuGenomics, Inc. CORP 5656 Acerta Pharma CORP 6101 Acessa Health, Inc.
    [Show full text]
  • Kyowa Hakko Kirin Co ., Ltd Fiscal 2008 First Half Results
    Kyowa Hakko Kirin Co ., Ltd Fiscal 2008 First Half Results October 30, 2008 President and Chief Executive Officer Yuzuru Matsuda Statements on results, forecasts and R&D status contained in this presentation represent judgments based on information available at the current time. Actual results may differ significantly due to a variety of factors such as economic conditions and exchange rate fluctuations. Separate service 65% 1 companies HD: Kirin by Other businesses Held by Kirin HD: Held by Kyowa Kirin: 35% subsidiary of Kirin Holdings Business integration 2011.1.1owned wholly a Will become 2009.4.1 Kirin Kyowa Foods Launched Kirin Food-Tech Other subsidiaries KYOWA HAKKO FOOD SPECIALTIES Kirin Co., Ltd. Kyowa Hakko Kirin Holdings KYOWA HAKKO CHEMICAL Mercian KYOWA HAKKO BIO Kirin Beverage Kirin Brewery Business structure (200810.1 ~) z z Outline of Fiscal 2008 firstfirst halfhalf rresultsesults Operating Recurring (¥bn) Net sales Net income income income FY08 H1 247.7 29.1 30.3 8.2 +55.1 +10.9 +12.2 -2.7 Change (+28.6%) (+59.8%) (+67.9%) (-25. 0%) FY07 H1 192.6 18.2 18.0 11.0 z Pharmaceuticals Sales and profits up due to Kirin Pharma integration, receipt of oneone--offoff payment from Amgen, etc. z Bio-Chemicals Sales and profits up due to growth in amino acids for intravenous liquids and pharmaceutical raw materials, and increased sales of health care products z Chemicals Sales up due to price revisions following rapid rise in fuel and raw materials prices but increased depreciation expense contributed to lower operating income z Food
    [Show full text]
  • Transforming Clinical Trials in Cardiovascular Disease Mission Critical for Health and Economic Well-Being
    VIEWPOINT Transforming Clinical Trials in Cardiovascular Disease Mission Critical for Health and Economic Well-being Elliott M. Antman, MD Perhaps the most exciting opportunity for CVD research- ers is to capitalize on the advances in systems and computa- Robert A. Harrington, MD tional biology that can inform first-in-human, proof-of- S EMPHASIZED BY THE BIPARTISAN POLICY CENTER, concept, and phase 2 dose-ranging trials in ways that were not healthcareexpendituresareanticipatedtoreach20% previously possible.4 Examples include using biomarkers, ge- of US gross domestic product by 2020 and are a netic observations, and definitions of pathophenotypes to adapt major threat to the sustainability of the health care the treatments being investigated. This is particularly rel- Asystem and to the economic productivity and stability of the evant to new treatments being explored for managing dyslip- country. Although death rates attributable to cardiovascular dis- idemia (eg, PCSK9 inhibition), diabetes, ischemic heart dis- ease (CVD) have declined by almost one-third over the last 11⁄2 ease, and heart failure—all topics that are among the 19 studies decades, CVD remains the leading cause of death and the bur- presented in the Clinical Science: Special Reports sessions at den of CVD remains unacceptably high, especially consider- the AHA meeting.2 As emphasized by the FDA in a draft guid- ing the aging of the population.1 The economic effects of the ance document, adaptive designs are encouraged during the burden of CVD are profound because managing
    [Show full text]
  • In Re Nuvelo, Inc. Securities Litigation 07-CV-04056-Second
    1 COUGHLIN STOIA GELLER RUDMAN & ROBBINS LLP 2 DENNIS J. HERMAN (220163) ELI R. GREENSTEIN 3 100 Pine Street, Suite 2600 4 San Francisco, CA 94111 Telephone : 415/288-4545 5 Fax: 415/288-4534 [email protected] 6 elig^a,csgrr.com 7 Liaison Counsel 8 BERGER & MONTAGE, P.C. IZARD NOBEL, LLP 9 SHERRIE R. SAVETT JEFFREY S. NOBEL CAROLE A. BRODERICK MARK P. KINDALL 10 BARBARA A. PODELL NANCY A. KULESA PHYLLIS M. PARKER SETH R. KLEIN 11 1622 Locust Street One Corporate Center 12 Philadelphia, PA 19103 One Church Street, Suite 1700 Telephone: 215/875-300 Hartford, CT 06103 13 Fax: 215/875-4604 Telephone: 860/493-6292 ssaveft@,,bm.net Fax: 860/493-6290 14 cbroderick@,bm.net [email protected] 15 bpodell@,,bm.et [email protected] pparker(&,,bm.net nkulesa(a,snilaw.com 16 [email protected] 17 Co-Lead Counsel for Plaintiffs 18 UNITED STATES DISTRICT COURT 19 NORTHERN DISTRICT OF CALIFORNIA 20 21 In re NUVELO, INC. SECURITIES Master File No. 3:07-cv-04056-VRW LITIGATION 22 CLASS ACTION 23 This Document Relates To: SECOND CONSOLIDATED COMPLAINT FOR VIOLATIONS OF THE FEDERAL 24 ALL ACTIONS. SECURITIES LAWS 25 26 27 28 1 TABLE OF CONTENTS 2 I. INTRODUCTION ...................................................................................................1 3 II. JURISDICTION AND VENUE ............................................................................ 15 4 III. PARTIES ............................................................................................................... 16 5 IV. CONFIDENTIAL WITNESSES ..........................................................................
    [Show full text]